# Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

> **NCT04804605** · PHASE3 · COMPLETED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 1220 (actual)

## Conditions studied

- Atopic Dermatitis Eczema

## Interventions

- **DRUG:** ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

## Key facts

- **NCT ID:** NCT04804605
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-25
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 1220 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04804605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04804605, "Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04804605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*